Azora Therapeutics, Inc. (DE)
Public company- Headquarters
- ENCINO, California
- Ticker
- ADIL
- CIK
- 0001513525
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CEOMatthew Davidson, Ph.D. | Oct 28, 2026 | Appointed |
| CFOCelia Economides | Oct 28, 2026 | Appointed |
| Chief Strategy OfficerJulie Saiki, Ph.D. | Oct 28, 2026 | Appointed |
| President and Chief Executive OfficeMatthew Davidson | Aug 13, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
CEO appointed: Matthew Davidson, Ph.D.
Matthew Davidson, Ph.D. was named President and Chief Executive Officer of Azora Therapeutics, Inc. (DE), effective October 28, 2026. Matthew Davidson, Ph.D. succeeds Cary J. Claiborne. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: President and Chief Executive Officer
- Executive appointment
CFO appointed: Celia Economides
Celia Economides was named Chief Financial Officer of Azora Therapeutics, Inc. (DE), effective October 28, 2026. Celia Economides succeeds Vinay Shah. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: Chief Financial Officer
- Executive appointment
Chief Strategy Officer appointed: Julie Saiki, Ph.D.
Julie Saiki, Ph.D. was named Chief Strategy Officer of Azora Therapeutics, Inc. (DE), effective October 28, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: Chief Strategy Officer
- Executive departure
CEO departs: Cary J. Claiborne
Cary J. Claiborne, President and Chief Executive Officer of Azora Therapeutics, Inc. (DE), leaves the role, effective October 28, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: President and Chief Executive Officer
- Executive departure
CFO departs: Vinay Shah
Vinay Shah, Chief Financial Officer of Azora Therapeutics, Inc. (DE), leaves the role, effective October 28, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 28, 2026Role: Chief Financial Officer
- Executive departure
CEO departs: Cary Claiborne
Cary Claiborne, President and Chief Executive Officer of Azora Therapeutics, Inc. (DE), leaves the role. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 13, 2026Role: President and Chief Executive Officer
- Executive appointment
President and Chief Executive Office appointed: Matthew Davidson
Matthew Davidson was named President and Chief Executive Office of Azora Therapeutics, Inc. (DE). The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 13, 2026Role: President and Chief Executive Office
- Executive departure
CFO departs: Vinay Shah
Vinay Shah, Chief Financial Officer of Azora Therapeutics, Inc. (DE), leaves the role. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 13, 2026Role: Chief Financial Officer
Last verified Nov 8, 2026